Our internationally recognised publications give you access to the expertise of hundreds of the world’s leading scientists, experts and researchers.

Our unrivalled collection of publications spans evidence-based clinical knowledge, research and regulatory information. The extensive breadth of content on MedicinesComplete supports your decision making, from research to the point of care and provides you with the world’s most trusted resources.

Subscribe Publication Updates

Publication Updates

14 Aug
Stockley's Interactions Checker_logo
Stockley’s Interaction Alerts August 2018 update

New and updated Alerts now available 

For August, 796 new Alerts have been added, and 2090 existing Alerts have been updated. 

14 Aug
Stockleys Drug Interactions_logo
Stockley’s Drug Interactions August 2018 update

Stockley’s Drug Interactions update with new and revised monographs. 

This update a new monoclonal antibodies chapter has been created, bringing all the monographs for these drugs into one place within the publication. The sections on the NRTIS and NNRTIs have been completely re-validated and updated. New drugs added for this update include abemaciclib, eluxadoline, lesinurad, ribociclib, sacubitril, and selexipag. 

14 Aug
AHFS Drug Information logo
AHFS Drug Information August 2018 update

This update contains 6 new monographs and 15 revised monographs.

New monographs: Factor Xa (recombinant), Inactivated-zhzo; Erenumab-aooe; Avatrombopag; Pegvaliase; Baricitinib; Lofexidine

Revised monographs: Editorial Staff; Crizotinib; PONATinib; Ceritinib; Perampanel; Alectinib; Daclizumab; Avelumab; Durvalumab; Brigatinib; Sodium Nitroprusside; Mebendazole; Primaquine; Riluzole; Albendazole

14 Aug
British National Formulary for Children logo
BNFC August 2018 update

This update contains 5 significant changes, 2 new preparations and 4 dose changes.

Significant Changes:

  • Diabetic complications: updated guidance.
  • Dolutegravir (Tivicay®, Triumeq®, Juluca®): signal of increased risk of neural tube defects; do not prescribe to women seeking to become pregnant; exclude pregnancy before initiation and advise use of effective contraception [MHRA/CHM advice].
  • Dyslipidaemias: updated guidance on familial hypercholesterolaemia.
  • Oropharyngeal infections, antibacterial therapy: updated guidance on sore throat (acute).
  • Vaccines: updated guidance for Meningococcal group B vaccines.

Dose Changes:

  • Canakinumab.
  • Haloperidol.
  • Mometasone furoate [prophylaxis and treatment of seasonal allergic or perennial rhinitis—age range extended].
  • Vancomycin [deletion of the statement recommending the use of ideal body-weight to calculate intravenous doses in obese patients].

New Preparations:

  • Firazyr® [icatibant].
  • Zemplar® [paricalcitol].

For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes

14 Aug
British National Formulary logo
BNF August 2018 update

This update contains 18 significant changes, 3 new preparations and 9 dose changes. 

Significant Changes:  

  • Age-related macular degeneration: updated guidance on management.
  • Arsenic trioxidefor treating acute promyelocytic leukaemia [NICE guidance]. 
  • Atezolizumabfor treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy [NICE guidance]. 
  • Brentuximab vedotinfor treating CD30-positive Hodgkin lymphoma [NICE guidance]. 
  • Cardiovascular disease risk assessment and prevention: updated guidance.
  • Denosumab(Xgeva®) for advanced malignancies involving bone: study data show new primary malignancies reported more frequently compared to zoledronate [MHRA/CHM advice]. 
  • Denosumab(Xgeva®) for giant cell tumour of bone: risk of clinically significant hypercalcaemia following discontinuation [MHRA/CHM advice]. 
  • Diabetic complications: updated guidance.
  • Dolutegravir(Tivicay®, Triumeq®, Juluca®): signal of increased risk of neural tube defects; do not prescribe to women seeking to become pregnant; exclude pregnancy before initiation and advise use of effective contraception [MHRA/CHM advice]. 
  • Donepezil hydrochloride, galantamine, rivastigmine, and memantine hydrochloridefor the treatment of Alzheimer’s disease [NICE guidance]. 
  • Dyslipidaemias: updated guidance on familial hypercholesterolaemia.
  • Glaucoma and ocular hypertension: updated guidance on management.
  • Guselkumabfor treating moderate to severe plaque psoriasis [NICE guidance]. 
  • Lynparza® (olaparib): risk of medication errors with new pharmaceutical form [MHRA/CHM advice].
  • Midostaurinfor untreated acute myeloid leukaemia [NICE guidance]. 
  • Oropharyngeal infections, antibacterial therapy: updated guidance on sore throat (acute).
  • Pembrolizumabfor untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable [NICE guidance]. 
  • Vaccines: updated guidance for Meningococcal group B vaccines.

Dose Changes: 

  • Canakinumab.
  • Ceritinib[dose and directions for administration]. 
  • Ciclosporin[rheumatoid arthritis indication and dose]. 
  • Collagenase[dosing statement for Dupuytren’s contracture]. 
  • Ferric maltol[indication]. 
  • Haloperidol.
  • Haloperidol decanoate.
  • Mometasone furoate[prophylaxis and treatment of seasonal allergic or perennial rhinitis— age range extended in children]. 
  • Vancomycin[deletion of the statement recommending the use of ideal body-weight to calculate intravenous doses in obese patients]. 

New PreparationsJuluca® [dolutegravir with rilpivirine], Kelhale® [beclometasone dipropionate], Lynparza® tablets [olaparib]. 

 
For further details on changes in the BNF click on http://www.medicinescomplete.com/mc/bnf/current/PHP107699-changes.htm 

10 Jul
The Green Guide logo
Green Guide July 2018 update

July 2018: Rules and Guidance for Pharmaceutical Distributors now updated

Update has been made to UK Guidance on Wholesale Distribution Practice – Appointment and Duties of the Responsible Person as well as The Responsible Person Gold Standard.

The section has been updated to incorporate sub-headings and text: Responsible Person, Eligibility requirements, Responsibilities of an RP, Obligations of the Licence Holder, Contract RPs, Small companies, Knowledge requirements, Experience requirements, Assessment of RP knowledge and experience, Reporting arrangements, Deputy RP and delegation of RP activities, Dispute resolution.  

View more